Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.55 |
| ▸ | PARP1 | P09874 | 4/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FER | P16591 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30124058 | 0.98 | PARP10 (0.53) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL19360742 | 0.83 | PARP10 (0.44) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL29380714 | 0.82 | LRRK2 (0.50) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL106149 | 0.82 | LRRK2 (0.50) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL16057480 | 0.80 | PARP11 (0.42) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL4455970 | 0.79 | PARP1 (0.57) | PARP10PARP11PARP1PDPK1LRRK2 | |
| SCHEMBL18626046 | 0.78 | PARP10 (0.40) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL68581 | 0.76 | MEN1 (0.61) | PARP10PARP11PARP1PDPK1PDGFRA | |
| SCHEMBL123812 | 0.74 | GAA (0.54) | MAOAALDH1A1KDM4EHSD17B10RAB9A | |
| SCHEMBL29408147 | 0.74 | GAA (0.54) | MAOAALDH1A1KDM4EHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024101965-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | 에스케이바이오팜 주식회사 | 2024-05-16 | — | — | WO | claimed |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2024163956-A2 | SIGMA RECEPTOR LIGAND COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-03-26 | — | — | US | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| CN-116528867-A | Compounds for the treatment of Alzheimer's disease | 艾伯塔大学理事会 | 2023-08-01 | — | — | CN | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7241767-B2 | Quinazoline(di)ones for invertebrate pest control | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20060199796-A1 | Substituted benzofused heterocycles | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP11 78/4885PARP1 202/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | PARP10 1785/4885PARP11 668/4885PARP1 707/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | PARP10 1254/4885PARP11 1717/4885PARP1 1148/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | PARP10 382/4885PARP11 261/4885PARP1 941/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP11 78/4885PARP1 202/4885 |
| US-20060199796-A1 | Substituted benzofused heterocycles | GPR119, SDHA, OGDH | PARP10 2182/4885PARP11 1400/4885PARP1 1809/4885 |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | IAPP, GPR119, APP | PARP10 3647/4885PARP11 4166/4885PARP1 4370/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP11 78/4885PARP1 202/4885 |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | IAPP, GPR119, APP | PARP10 3647/4885PARP11 4166/4885PARP1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.